Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,416 GBX | -0.10% |
|
+0.06% | +16.83% |
01:20pm | ASTRAZENECA : Goldman Sachs maintains a Buy rating | ZD |
10:34am | AstraZeneca disappointed by breast cancer drug trial results | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.83% | 244B | |
+51.83% | 797B | |
+40.45% | 628B | |
-6.71% | 351B | |
+17.05% | 323B | |
+9.98% | 300B | |
+0.94% | 223B | |
+5.52% | 163B | |
-5.64% | 153B | |
-1.69% | 118B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Type-2 Diabetes Drug Wins Pediatric Approval in US